.png "Cara Therapeutics (NASDAQ: CARA)")
Canaccord Genuity analyst Arlinda Lee maintained a Buy rating on Cara Therapeutics (NASDAQ: CARA) today and set a price target of $22. The company’s shares closed yesterday at $18.06.
According to TipRanks.com, Lee is a 2-star analyst with an average return of 0.3% and a 42.6% success rate. Lee covers the Healthcare sector, focusing on stocks such as Karyopharm Therapeutics, Aquinox Pharmaceuticals, and Zynerba Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cara Therapeutics with a $24.20 average price target, implying a 34.0% upside from current levels. In a report released yesterday, Needham also maintained a Buy rating on the stock with a $28 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $27.35 and a one-year low of $11.11. Currently, Cara Therapeutics has an average volume of 1.18M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CARA Therapeutics, Inc. engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain.
Read More on CARA:
